Literature DB >> 33377136

Burden of Proof: Evaluating the Efficacy of Tumor Mutational Burden (TMB) in Predicting Response to Immune Checkpoint Inhibitors.

James Newman1, Nagashree Seetharamu1, Muhammad Wasif Saif1.   

Abstract

Entities:  

Keywords:  Cancer; Immune checkpoint inhibitors (ICIs); Microsatellite instability-high (MSI-H); Microsatellite stable (MSS); POLD1; POLE; Tumor mutational burden (TMB)

Year:  2020        PMID： 33377136      PMCID： PMC7769129     

Source DB:  PubMed          Journal:  Cancer Med J


× No keyword cloud information.
  22 in total

1.  Evaluation of POLE and POLD1 Mutations as Biomarkers for Immunotherapy Outcomes Across Multiple Cancer Types.

Authors:  Feng Wang; Qi Zhao; Ying-Nan Wang; Ying Jin; Ming-Ming He; Ze-Xian Liu; Rui-Hua Xu
Journal:  JAMA Oncol       Date:  2019-10-01       Impact factor: 31.777

2.  Tumor mutation burden in lung cancer: a new predictive biomarker for immunotherapy or too soon to tell?

Authors:  Mariam Alexander; Jose Galeas; Haiying Cheng
Journal:  J Thorac Dis       Date:  2018-11       Impact factor: 2.895

3.  Response to PD-1 Blockade in Microsatellite Stable Metastatic Colorectal Cancer Harboring a POLE Mutation.

Authors:  Jun Gong; Chongkai Wang; Peter P Lee; Peiguo Chu; Marwan Fakih
Journal:  J Natl Compr Canc Netw       Date:  2017-02       Impact factor: 11.908

4.  Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer.

Authors:  A B Schrock; C Ouyang; J Sandhu; E Sokol; D Jin; J S Ross; V A Miller; D Lim; I Amanam; J Chao; D Catenacci; M Cho; F Braiteh; S J Klempner; S M Ali; M Fakih
Journal:  Ann Oncol       Date:  2019-07-01       Impact factor: 32.976

5.  Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.

Authors:  Robert J Motzer; Nizar M Tannir; David F McDermott; Osvaldo Arén Frontera; Bohuslav Melichar; Toni K Choueiri; Elizabeth R Plimack; Philippe Barthélémy; Camillo Porta; Saby George; Thomas Powles; Frede Donskov; Victoria Neiman; Christian K Kollmannsberger; Pamela Salman; Howard Gurney; Robert Hawkins; Alain Ravaud; Marc-Oliver Grimm; Sergio Bracarda; Carlos H Barrios; Yoshihiko Tomita; Daniel Castellano; Brian I Rini; Allen C Chen; Sabeen Mekan; M Brent McHenry; Megan Wind-Rotolo; Justin Doan; Padmanee Sharma; Hans J Hammers; Bernard Escudier
Journal:  N Engl J Med       Date:  2018-03-21       Impact factor: 91.245

6.  Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study.

Authors:  Aurélien Marabelle; Marwan Fakih; Juanita Lopez; Manisha Shah; Ronnie Shapira-Frommer; Kazuhiko Nakagawa; Hyun Cheol Chung; Hedy L Kindler; Jose A Lopez-Martin; Wilson H Miller; Antoine Italiano; Steven Kao; Sarina A Piha-Paul; Jean-Pierre Delord; Robert R McWilliams; David A Fabrizio; Deepti Aurora-Garg; Lei Xu; Fan Jin; Kevin Norwood; Yung-Jue Bang
Journal:  Lancet Oncol       Date:  2020-09-10       Impact factor: 41.316

7.  Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.

Authors:  Robert J Motzer; Bernard Escudier; David F McDermott; Saby George; Hans J Hammers; Sandhya Srinivas; Scott S Tykodi; Jeffrey A Sosman; Giuseppe Procopio; Elizabeth R Plimack; Daniel Castellano; Toni K Choueiri; Howard Gurney; Frede Donskov; Petri Bono; John Wagstaff; Thomas C Gauler; Takeshi Ueda; Yoshihiko Tomita; Fabio A Schutz; Christian Kollmannsberger; James Larkin; Alain Ravaud; Jason S Simon; Li-An Xu; Ian M Waxman; Padmanee Sharma
Journal:  N Engl J Med       Date:  2015-09-25       Impact factor: 91.245

8.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.

Authors:  Hossein Borghaei; Luis Paz-Ares; Leora Horn; David R Spigel; Martin Steins; Neal E Ready; Laura Q Chow; Everett E Vokes; Enriqueta Felip; Esther Holgado; Fabrice Barlesi; Martin Kohlhäufl; Oscar Arrieta; Marco Angelo Burgio; Jérôme Fayette; Hervé Lena; Elena Poddubskaya; David E Gerber; Scott N Gettinger; Charles M Rudin; Naiyer Rizvi; Lucio Crinò; George R Blumenschein; Scott J Antonia; Cécile Dorange; Christopher T Harbison; Friedrich Graf Finckenstein; Julie R Brahmer
Journal:  N Engl J Med       Date:  2015-09-27       Impact factor: 91.245

9.  Beyond microsatellite testing: assessment of tumor mutational burden identifies subsets of colorectal cancer who may respond to immune checkpoint inhibition.

Authors:  David A Fabrizio; Thomas J George; Richard F Dunne; Garrett Frampton; James Sun; Kyle Gowen; Mark Kennedy; Joel Greenbowe; Alexa B Schrock; Aram F Hezel; Jeffrey S Ross; Phillip J Stephens; Siraj M Ali; Vincent A Miller; Marwan Fakih; Samuel J Klempner
Journal:  J Gastrointest Oncol       Date:  2018-08

10.  Germline and somatic polymerase ε and δ mutations define a new class of hypermutated colorectal and endometrial cancers.

Authors:  Sarah Briggs; Ian Tomlinson
Journal:  J Pathol       Date:  2013-06       Impact factor: 7.996
View more
  1 in total

Review 1.  Perspectives on Immunotherapy of Metastatic Colorectal Cancer.

Authors:  Yongjiu Dai; Wenhu Zhao; Lei Yue; Xinzheng Dai; Dawei Rong; Fan Wu; Jian Gu; Xiaofeng Qian
Journal:  Front Oncol       Date:  2021-06-09       Impact factor: 6.244
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.